JP2019081790 METHODS OF TREATING PANCREATIC CANCER

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Office

Japan

Application Number 2019033910

Application Date 27.02.2019

Publication Number 2019081790

Publication Date 30.05.2019

Publication Kind A

IPC

View more classifications

View less classifications

CPC

View more classifications

View less classifications

Applicants ABRAXIS BIOSCIENCE LLC
アブラクシス　バイオサイエンス，　エルエルシー

Inventors NEIL P DESAI
ニール　ピー．　デサイ
MARKUS RENSCHLER
マルクス　レンシュラー

Agents 山尾　憲人
品川　永敏
釜平　双美
水原　正弘
呉　英燦

Priority Data 13794480 11.03.2013 US
61/751,820 11.01.2013 US
61/752,355 14.01.2013 US

Title

(EN) METHODS OF TREATING PANCREATIC CANCER

(JA) 膵臓がんの処置方法

Abstract

(EN)

PROBLEM TO BE SOLVED: To provide methods of treating pancreatic cancer.

SOLUTION: Provided herein are methods of treating metastatic pancreatic cancer in an individual (such as a human individual), the methods comprising administering to the individual (i) an effective amount of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and an albumin and (ii) an effective amount of gemcitabine. In some embodiments, there is provided a method of treating locally advanced unresectable pancreatic cancer in an individual (such as a human individual), the method comprising administering to the individual (i) an effective amount of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and an albumin and (ii) an effective amount of gemcitabine. In some embodiments according to (or as applied to) any of the embodiments described herein, the pancreatic cancer is pancreatic adenocarcinoma.

SELECTED DRAWING: None

(JA)

【課題】膵臓がんの処置方法を提供する。
【解決手段】個体（ヒト個体など）における転移性膵臓がんを処置する方法が本明細書で
提供され、この方法は、（ｉ）タキサン（パクリタキセルなど）およびアルブミンを含む
ナノ粒子を含む有効量の組成物；ならびに（ｉｉ）有効量のゲムシタビンを、上記個体に
投与するステップを含む。一部の実施形態では、個体（ヒト個体など）における局所進行
切除不能な膵臓がんを処置する方法が提供され、この方法は、（ｉ）タキサン（パクリタ
キセルなど）およびアルブミンを含むナノ粒子を含む有効量の組成物；ならびに（ｉｉ）
有効量のゲムシタビンを、上記個体に投与するステップを含む。本明細書に記載される実
施形態のいずれかに従う（またはそれらに適用される）一部の実施形態では、この膵臓が
んは膵臓腺癌である。
【選択図】なし

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
33	Heterocyclic compounds
335	having oxygen as the only ring hetero atom, e.g. fungichromin
337	having four-membered rings, e.g. taxol

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
10	Dispersions; Emulsions

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
14	Particulate form, e.g. powders

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
48	Preparations in capsules, e.g. of gelatin, of chocolate
50	Microcapsules
51	Nanocapsules

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
48	Preparations in capsules, e.g. of gelatin, of chocolate
52	Sustained or differential release type
54	containing discrete particles with coatings of different thicknesses or different materials
56	Organic coatings
64	containing proteins or derivatives thereof

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. JP2019081790 - METHODS OF TREATING PANCREATIC CANCER

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1	Drugs for disorders of the alimentary tract or the digestive system
18	for pancreatic disorders, e.g. pancreatic enzymes

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30	Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
42	Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
48	Preparations in capsules, e.g. of gelatin, of chocolate
50	Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
51	Nanocapsules; Nanoparticles;
5107	Excipients; Inactive ingredients
513	Organic macromolecular compounds; Dendrimers
5169	Proteins, e.g. albumin, gelatin

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
48	Preparations in capsules, e.g. of gelatin, of chocolate
50	Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
51	Nanocapsules; Nanoparticles;
5107	Excipients; Inactive ingredients
513	Organic macromolecular compounds; Dendrimers
5169	Proteins, e.g. albumin, gelatin